Monitoring Lurbinectedin's Main Side Effects
Lurbinectedin's label (Zepzelca) requires monitoring for hematologic toxicity, including complete blood counts (CBCs) with differential prior to each cycle and as clinically indicated, due to frequent neutropenia, anemia, and thrombocytopenia. Patients with grade 3 or 4 neutropenia should delay until recovery to grade 1 or less.[1]
How Often to Check Liver Function
Assess liver enzymes (ALT, AST, bilirubin) prior to initiating treatment and before each cycle. Interrupt or reduce dose for grade 3 elevations; discontinue for grade 4 or persistent grade 3.[1]
Testing for Kidney Function and Electrolytes
Monitor serum creatinine and electrolytes (including potassium, magnesium, calcium) before each cycle, as renal impairment or electrolyte shifts can occur, sometimes linked to rhabdomyolysis or tumor lysis.[1]
Cardiac Monitoring Schedule
Perform ECGs prior to treatment and periodically during therapy if baseline abnormalities exist. Echocardiograms or multigated acquisition scans are needed before starting and as clinically warranted for ejection fraction drops.[1]
Why Frequency Varies by Patient Risk
High-risk patients (e.g., prior myelosuppression, hepatic impairment) need more frequent CBCs or labs during cycles. Guidelines emphasize weekly checks for severe cytopenias until resolution.[1][2]
[1]: Zepzelca (lurbinecteddin) Prescribing Information, Jazz Pharmaceuticals, https://www.zepzelca.com/pdf/Zepzelca-PI.pdf
[2]: NCCN Guidelines for Small Cell Lung Cancer, Version 3.2024, https://www.nccn.org/guidelines